Want to see AU:NX1 full AI Analyst Report?
NX1 Stock Chart & Stats
AU$0.02
>-AU$0.01(-6.45%)
At close: 4:00 PM EST
AU$0.02
>-AU$0.01(-6.45%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.04
Previous CloseN/A
VolumeN/A
Average Volume (3M)64.62K
Market Cap
AU$2.28M
Enterprise ValueAU$2.94M
Total Cash (Recent Filing)AU$481.32K
Total Debt (Recent Filing)AU$336.25K
Price to Earnings (P/E)―
Beta-1.63
Next Earnings
Feb 22, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding253,037,320
10 Day Avg. Volume0
30 Day Avg. Volume64,624
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-116.78
Price to Sales (P/S)22.29
P/FCF Ratio-20.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageAbsolute debt levels are very small (~34k) which limits interest burden and reduces refinancing pressure. Low financial leverage gives the company structural flexibility to prioritize operational stabilization or raise equity without immediate debt servicing constraints, helping medium-term resilience.
High Gross MarginA 100% reported gross margin suggests strong product-level economics or low incremental COGS. If sustainable, this creates a structural opportunity to reach profitability through operating expense control and scale. High gross margins improve long-run operating leverage potential.
Improving Cash BurnA material reduction in operating cash outflow indicates management has cut costs or improved near-term cash conversion. This structural improvement extends runway and provides more time to stabilize revenue or secure financing, reducing near-term solvency pressure if the trend continues.
Bears Say
Volatile, Shrinking RevenueA 62% YoY revenue decline and prior volatility indicate an unstable commercial base and weak demand predictability. Structural revenue instability undermines scaling, makes long-term planning difficult, and increases reliance on one-off sales or funding to cover fixed costs and product development.
Negative Shareholders' EquityEquity deterioration into negative territory materially weakens the balance sheet, reducing financial flexibility and increasing creditor scrutiny. Negative equity is a structural solvency signal that limits M&A or financing options and raises long-term viability concerns without capital injections.
Persistent Negative Cash FlowChronic negative operating and free cash flow means the business cannot self-fund operations or growth. Over the medium term this creates dependency on external capital, which can be dilutive or restrictive and constrains investment in commercialization and R&D needed for sustainable growth.
InhaleRx Limited News
NX1 FAQ
What was InhaleRx Limited’s price range in the past 12 months?
InhaleRx Limited lowest share price was <AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is InhaleRx Limited’s market cap?
InhaleRx Limited’s market cap is AU$2.28M.
When is InhaleRx Limited’s upcoming earnings report date?
InhaleRx Limited’s upcoming earnings report date is Feb 22, 2027 which is in 118 days.
How were InhaleRx Limited’s earnings last quarter?
InhaleRx Limited released its earnings results on Aug 31, 2026. The company reported -AU$0.005 earnings per share for the quarter.
Is InhaleRx Limited overvalued?
According to Wall Street analysts InhaleRx Limited’s price is currently Overvalued.
Does InhaleRx Limited pay dividends?
InhaleRx Limited does not currently pay dividends.
What is InhaleRx Limited’s EPS estimate?
InhaleRx Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InhaleRx Limited have?
InhaleRx Limited has 253,037,320 shares outstanding.
What happened to InhaleRx Limited’s price movement after its last earnings report?
InhaleRx Limited reported an EPS of -AU$0.005 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of InhaleRx Limited?
Currently, no hedge funds are holding shares in AU:NX1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InhaleRx Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
296.01%
Trailing 12-Months
Asset Growth
13.15%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
InhaleRx Limited
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.
Technical Analysis
Somnomed Limited
―
Cyclopharm Limited
―
Adherium Ltd.
―
4DMedical Ltd
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―